Blinatumomab is changing the standard of care paradigms of newly diagnosed and relapsed pediatric B-cell acute lymphoblastic leukemia

Le résumé fourni par la source

Summary Since 2016, a relevant number of phase I, II, and III trials performed with children and adolescents with CD19-positive B‑cell acute lymphoblastic leukemia (B-ALL) have studied the use of the bi-specific T‑cell engager antibody blinatumomab with respect to both improving disease outcomes and reducing therapy-related toxicities. All studies reported to date, from infants to older adults with B‑ALL, have shown a definitive advantage for blinatumomab intercalated into multidrug chemotherapy regimens or, in some trials, as a replacement of intensive chemotherapy phases. Conclusively, blinatumomab-based therapy is rapidly being established as the new standard of care for treatment of pediatric patients ≥ 1 month of age with CD19 + B-ALL as part of consolidation of a multiphase chemotherapy. The story of the success of blinatumomab in childhood B‑ALL is summarized in the current review article.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.